Drug Profile
Research programme: brain cancer therapeutics - DURECT Corporation
Alternative Names: Brain cancer therapeutics research programme - DURECT CorporationLatest Information Update: 28 Mar 2012
Price :
$50
*
At a glance
- Originator DURECT Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer